Akari Therapeutics' (AKTX) shares skyrocket 175% after 'successful' pre-IND FDA meeting

NASDAQ: AKTX | Akari Therapeutics Plc News, Ratings, and Charts

AKTX – Shares of Akari Therapeutics PLC more than doubled, toward a 15-month high in very active morning trade Wednesday.

Shares of Akari Therapeutics PLC AKTX, +196.14% more than doubled–soaring 145%–toward a 15-month high in very active morning trade Wednesday, enough to pace all the gainers on the Nasdaq exchange, after the company said it plans to commence trials in European and U.S. pediatric patients this year for its treatment of pediatric thrombotic microangiopathy. Trading volume rocketed to 22.3 million shares, compared with the full-day average of about 20,000 shares. The company said it had a “successful,” pre-investigational new drug (IND) meeting with the Food and Drug Administration regarding its pivotal clinical trial program for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), which is an orphan condition with an estimated fatality rate of 80%. Chief Executive Clive Richardson said trials in HSCT-TMA patients are planned to begin in the fourth quarter. “We see HSCT-TMA as a gateway indication into a range of other poorly treated orphan TMAs, and are enthusiastic about the potential of Coversin to offer an improved standard of care for patients with these rare and usually fatal conditions,” Richardson said. The stock has now run up 93% over the past 12 months, while the iShares Nasdaq Biotechnology ETF IBB, +1.19% has slipped 1.1% and the S&P 500 SPX, +0.87%gained 0.9%.


Akari Therapeutics PLC ADR shares were trading at $4.80 per share on Wednesday morning, up $2.98 (+163.74%). Year-to-date, AKTX has gained 205.73%, versus a 12.66% rise in the benchmark S&P 500 index during the same period.

AKTX currently has a StockNews.com POWR Rating of D (Sell), and is ranked #180 of 315 stocks in the Biotech category.


This article is brought to you courtesy of MarketWatch.

9 "Must Own" Growth Stocks For 2019

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Top Stories on StockNews.com

NYSE: TWTR | Twitter, Inc. Common Stock News, Ratings, and Charts

Twitter (TWTR): Buy, Hold Sell? Get the POWR Ratings Breakdown

The StockNews POWR Ratings only computes to a C (Neutral), but Steve Reitmeister sees more upside potential for long term investors.
NYSE: DIS | Walt Disney Company (The) Common Stock News, Ratings, and Charts

Disney's (DIS) new live-action film, Aladdin, expected to make $80 million this weekend

The live-action “Aladdin” film starring Will Smith is expected to lead the box office over the Memorial Day holiday weekend.
NYSE: SQ | Square, Inc. Class A Common Stock News, Ratings, and Charts

Is Square (SQ) stock a good buy at this price level?

SQ stock now trades for just $65.
NYSE: F | Ford Motor Company Common Stock News, Ratings, and Charts

Is it possible Ford (F) would buy Tesla (TSLA)

Making a deal work would be a challenge.
NASDAQ: CVCO | Cavco Industries, Inc. News, Ratings, and Charts

Best & Worst Performing Stock Industries for May 24, 2019

Led by ticker CVCO, "Homebuilders" was our best performing stock industry of the day, with a 2.60% gain.

Read More Stories


More Akari Therapeutics Plc (AKTX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All AKTX News
Page generated in 1.0651 seconds.